<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37730825</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Trends and practices following the 2016 hydroxychloroquine screening guidelines.</ArticleTitle><Pagination><StartPage>15618</StartPage><MedlinePgn>15618</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15618</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-42816-5</ELocationID><Abstract><AbstractText>This study aimed to understand the profile of hydroxychloroquine-treated patients, referral patterns, and dosing and to assess the adherence of eye care providers to the latest 2016 screening guidelines provided by the American Academy of Ophthalmology. Patients were identified using electronic health records (EHR) taking hydroxychloroquine and were seen by optometrists, retinal specialists, and non-retinal ophthalmologists. Review of EHR data includes demographic characteristics, indications, and dosing profile of hydroxychloroquine use, eye care provider managing the patient, and imaging modalities performed. A total of 166 patients were included in the study. The most common indications for screening were systemic lupus erythematosus and discoid lupus (52.4%) followed by rheumatoid arthritis (18.7%) and Sj&#xf6;gren's syndrome (9.6%). Ninety-two (55.4%) patients were on a higher-than-recommended dose of&#x2009;&gt;&#x2009;5&#xa0;mg/kg/day. Patients who weighed less (mean 63.9&#xa0;kg) were taking a higher-than-recommended dose (vs. 81.5&#xa0;kg, p&#x2009;&lt;&#x2009;0.001). Although retinal specialists adhered best to the use of all three recommended imaging modalities, visual field testing was done appropriately for only 8.3% of Asian and 71.1% of non-Asian patients. In conclusion, there is substantial variability in screening by ophthalmic providers and prescribing practices compared with the current recommendations. In particular, there is a marked deficiency in correct visual field testing in Asian patients. These findings are important to highlight potential interventions to improve screening for hydroxychloroquine toxicity.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kalaw</LastName><ForeName>Fritz Gerald P</ForeName><Initials>FGP</Initials><AffiliationInfo><Affiliation>Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jacobs Retina Center, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Arnett</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Sally L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology, 9415 Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Department of Biomedical Informatics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92161, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borooah</LastName><ForeName>Shyamanga</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA. sborooah@health.ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jacobs Retina Center, University of California San Diego, 9415, Campus Point Drive, La Jolla, CA, 92093, USA. sborooah@health.ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP5 OD029610</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD032644</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000047" MajorTopicYN="N">Academies and Institutes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>23</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37730825</ArticleId><ArticleId IdType="pmc">PMC10511627</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-42816-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-42816-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From Malaria to Autoimmunity. Clin. Rev. Allergy Immunol. 2012;42:145&#x2013;153. doi: 10.1007/s12016-010-8243-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-010-8243-x</ArticleId><ArticleId IdType="pmc">PMC7091063</ArticleId><ArticleId IdType="pubmed">21221847</ArticleId></ArticleIdList></Reference><Reference><Citation>Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther. Adv. Musculoskelet. Dis. 2022;14:1759720x2110730. doi: 10.1177/1759720X211073001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X211073001</ArticleId><ArticleId IdType="pmc">PMC8848057</ArticleId><ArticleId IdType="pubmed">35186126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, Feng L, Teng Y, Cheng Y, Feng J. Management of multiple neurological complications in mixed connective tissue disease: A case report. Medicine. 2018;97:e11360. doi: 10.1097/MD.0000000000011360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011360</ArticleId><ArticleId IdType="pmc">PMC6081063</ArticleId><ArticleId IdType="pubmed">30075502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. The Efficiency of hydroxychloroquine for the treatment of primary Sj&#xf6;gren&#x2019;s syndrome: A systematic review and meta-analysis. Front. Pharmacol. 2021;12:693796. doi: 10.3389/fphar.2021.693796.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.693796</ArticleId><ArticleId IdType="pmc">PMC8475756</ArticleId><ArticleId IdType="pubmed">34588979</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazir AM, et al. Evaluating the use of hydroxychloroquine in treating patients with rheumatoid arthritis. Cureus. 2021 doi: 10.7759/cureus.19308.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19308</ArticleId><ArticleId IdType="pmc">PMC8575345</ArticleId><ArticleId IdType="pubmed">34765383</ArticleId></ArticleIdList></Reference><Reference><Citation>Skorupa T, Shmerling RH. Adherence to weight-based dosing guidelines in patients receiving hydroxychloroquine for systemic lupus erythematosus and rheumatoid arthritis: Results of a quality improvement initiative. ACR Open Rheumatol. 2021;3:733&#x2013;737. doi: 10.1002/acr2.11320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11320</ArticleId><ArticleId IdType="pmc">PMC8516102</ArticleId><ArticleId IdType="pubmed">34363746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology. 2016;55:957&#x2013;967. doi: 10.1093/rheumatology/kev357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev357</ArticleId><ArticleId IdType="pubmed">26428520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundelin SP, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 2002;110:481&#x2013;489. doi: 10.1034/j.1600-0463.2002.100606.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0463.2002.100606.x</ArticleId><ArticleId IdType="pubmed">12193209</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza Botelho M, et al. Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. Syst. Rev. 2021;10:294. doi: 10.1186/s13643-021-01835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-021-01835-x</ArticleId><ArticleId IdType="pmc">PMC8567984</ArticleId><ArticleId IdType="pubmed">34736537</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrulli S, et al. Quantitative autofluorescence findings in patients undergoing hydroxychloroquine treatment. Clin. Exp. Ophthalmol. 2022;50:500&#x2013;509. doi: 10.1111/ceo.14090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.14090</ArticleId><ArticleId IdType="pmc">PMC9545387</ArticleId><ArticleId IdType="pubmed">35503294</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109:1377&#x2013;1382. doi: 10.1016/S0161-6420(02)01168-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(02)01168-5</ArticleId><ArticleId IdType="pubmed">12093666</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415&#x2013;422. doi: 10.1016/j.ophtha.2010.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2010.11.017</ArticleId><ArticleId IdType="pubmed">21292109</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology. 2016;123:1386&#x2013;1394. doi: 10.1016/j.ophtha.2016.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman S, et al. Implementation of recommendations for the screening of hydroxychloroquine retinopathy: Poor adherence of rheumatologists and ophthalmologists. Lupus. 2017;26:277&#x2013;281. doi: 10.1177/0961203316660204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316660204</ArticleId><ArticleId IdType="pubmed">27440459</ArticleId></ArticleIdList></Reference><Reference><Citation>Semmer AE, Lee MS, Harrison AR, Olsen TW. Hydroxychloroquine retinopathy screening. Br. J. Ophthalmol. 2008;92:1653&#x2013;1655. doi: 10.1136/bjo.2008.144402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.2008.144402</ArticleId><ArticleId IdType="pmc">PMC4397565</ArticleId><ArticleId IdType="pubmed">18829634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol. 2014;132:1199. doi: 10.1001/jamaophthalmol.2014.1720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.1720</ArticleId><ArticleId IdType="pmc">PMC4192095</ArticleId><ArticleId IdType="pubmed">24970348</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning DJ. Impact of the revised American academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am. J. Ophthalmol. 2013;155:418&#x2013;428.e1. doi: 10.1016/j.ajo.2012.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2012.09.025</ArticleId><ArticleId IdType="pubmed">23218706</ArticleId></ArticleIdList></Reference><Reference><Citation>Au A, et al. Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. Am. J. Ophthalmol. 2015;160:561&#x2013;568.e2. doi: 10.1016/j.ajo.2015.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2015.06.009</ArticleId><ArticleId IdType="pubmed">26116260</ArticleId></ArticleIdList></Reference><Reference><Citation>Braslow RA, Shiloach M, Macsai MS. Adherence to hydroxychloroquine dosing guidelines by rheumatologists. Ophthalmology. 2017;124:604&#x2013;608. doi: 10.1016/j.ophtha.2016.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.12.021</ArticleId><ArticleId IdType="pubmed">28153440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu ST, Ponugoti A, Deaner JD, Vajzovic L. Update on retinal drug toxicities. Curr. Ophthalmol. Rep. 2021;9:168&#x2013;177. doi: 10.1007/s40135-021-00277-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40135-021-00277-x</ArticleId><ArticleId IdType="pmc">PMC8688906</ArticleId><ArticleId IdType="pubmed">34956737</ArticleId></ArticleIdList></Reference><Reference><Citation>Winebrake J, et al. Rheumatologists&#x2019; perspective on hydroxychloroquine guidelines. Lupus Sci. Med. 2020;7:e000427. doi: 10.1136/lupus-2020-000427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000427</ArticleId><ArticleId IdType="pmc">PMC7640534</ArticleId><ArticleId IdType="pubmed">33148665</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum JT, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis Rheumatol. 2021;73:908&#x2013;911. doi: 10.1002/art.41683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41683</ArticleId><ArticleId IdType="pubmed">33559327</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelbaky MSE, El Mamoun TA, Mabrouk FI, Hassan RM. Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus, Egypt. J. Intern. Med. 2021;33:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184260</ArticleId><ArticleId IdType="pubmed">34121836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775&#x2013;784. doi: 10.1002/acr.20133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20133</ArticleId><ArticleId IdType="pubmed">20535788</ArticleId></ArticleIdList></Reference><Reference><Citation>Daftarian N, et al. RetINal toxicity and hydroxychloroquine therapy (INTACT): Protocol for a prospective population-based cohort study. BMJ Open. 2022;12:e053852. doi: 10.1136/bmjopen-2021-053852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-053852</ArticleId><ArticleId IdType="pmc">PMC8860004</ArticleId><ArticleId IdType="pubmed">35177450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao J-H, et al. Characteristics and potential risk factors of hydroxychloroquine retinopathy in patients with systemic lupus erythematosus: Focusing on Asian population. J. Ocul. Pharmacol. Ther. 2022;38:728&#x2013;733. doi: 10.1089/jop.2022.0060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2022.0060</ArticleId><ArticleId IdType="pubmed">36206015</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmani Z, et al. Hydroxychloroquine treatment in European patients with lupus erythematosus: Dosing, retinopathy screening and adherence. Lupus Sci. Med. 2021;8:e000478. doi: 10.1136/lupus-2021-000478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000478</ArticleId><ArticleId IdType="pmc">PMC8021889</ArticleId><ArticleId IdType="pubmed">33795484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RI, et al. Impact of an electronic decision support tool to improve ophthalmic safety in hydroxychloroquine prescribing practices. Ophthalmic Surg. Lasers Imaging Retina. 2022;53:310&#x2013;316. doi: 10.3928/23258160-20220601-02.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20220601-02</ArticleId><ArticleId IdType="pubmed">35724373</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453. doi: 10.1001/jamaophthalmol.2014.3459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KE, Ryu SJ, Kim YH, Seo Y, Ahn SJ. Visual field examinations using different strategies in Asian patients taking hydroxychloroquine. Sci. Rep. 2022;12:14778. doi: 10.1038/s41598-022-19048-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-19048-0</ArticleId><ArticleId IdType="pmc">PMC9427842</ArticleId><ArticleId IdType="pubmed">36042337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>